[email protected] +44 20 8123 2220 (UK) +1 732 587 5005 (US) Contact Us | FAQ |

Pharmaceutical Contract Manufacturing Market by Service (Pharmaceutical (API, FDF - Tablet, Capsule, Injectable)), Biologic (API, FDF), Drug Development), End User (Big Pharma, Small & Medium-sized Pharma, Generic Pharma) - Global Forecast to 2028

April 2023 | 279 pages | ID: P0C005CEE7CEN
MarketsandMarkets

US$ 3,465.00 US$ 4,950.00 -30 %
Offer valid until March 31, 2024!

E-mail Delivery (PDF)

Download PDF Leaflet

Accepted cards
Wire Transfer
Checkout Later
Need Help? Ask a Question
The global pharmaceutical contract development and manufacturing market size is projected to reach USD 258.3 billion by 2028 from USD 176.5 billion in 2023, at a CAGR of 7.9% during the forecast period. Factors such as increasing demand for generics due to their low cost and the looming patent expiry of blockbuster medications have pushed companies to focus on core functions, supporting the demand for CDMO services, and driving the market growth at a faster pace.

“The biologic manufacturing service segment is likely to grow at the highest CAGR during the forecast period of 2023-2028.”

On the basis of service, the pharmaceutical contract development and manufacturing market is segmented into pharmaceutical manufacturing service, drug development service, and biologic manufacturing service. The biologic manufacturing service segment is projected to grow at the highest CAGR during the forecast period. The growth is attributed to the rising demand for biologics, targeted drug therapies, and increase in the number cell & gene therapy pipeline studies. These factors are likely to have a positive impact on segmental growth.

“The big pharmaceutical companies segment is likely to grow at the highest CAGR during the forecast period of 2023-2028.”

Based on end user, the pharmaceutical contract development and manufacturing market is segmented into big pharmaceutical companies, small and midsized pharmaceutical companies, generic pharmaceutical companies, and other end users (Academic Institutes, Small CDMOs, and CROs). The big pharmaceutical companies segment held a dominant share of the pharmaceutical contract development and manufacturing market, in 2022. The large share of this segment is attributed to the growing focus of pharma giants on core activities like increasing R&D for the discovery & development of new molecules, pushing them to outsource the manufacturing services. This is one of the major factors anticipated to project market growth.

“Asia Pacific region is likely to grow at a faster pace.”

The pharmaceutical contract development and manufacturing market is divided into North America, Europe, the Asia Pacific, Latin America, and the Middle East & Africa. In 2022, North America accounted for the dominant share of the pharmaceutical contract development and manufacturing market. The dominance of the region is attributable to various factors such as the presence of leading players in the region coupled with the ongoing research activities of pharmaceutical contract development and manufacturing. Asia Pacific region is likely to grow at a faster pace owing to various factors such as the growing awareness of personalized therapeutics, rising government initiatives for generic medicines in the region, and the emergence of new market players in the pharmaceutical contract development and manufacturing market.

The primary interviews conducted for this report can be categorized as follows:
  • By Respondent: Supply Side- 60%, and Demand Side - 40%
  • By Designation (Supply Side): Managers - 45%, CXOs & Directors - 25%, Executives- 15%, Other -15.0%
  • By Region: North America -40%, Europe -25%, Asia-Pacific -20%, Latin America -10%, and Middle East and Africa -5%
Lists of Companies Profiled in the Report:
  • Thermo Fisher Scientific, Inc. (US)
  • Catalent, Inc. (US)
  • Lonza Group (Switzerland)
  • AbbVie, Inc. (US)
  • WuXi AppTec (China)
  • Evonik Industries AG (Germany)
  • Samsung Biologics. (South Korea)
  • Boehringer Ingelheim International GmbH. (Germany)
  • Siegfried Holding AG (Switzerland)
  • Piramal Pharma Solutions (India)
  • Recipharm AB. (Sweden)
  • Eurofins Scientific (Luxembourg)
  • FUJIFILM Holdings Corporation (Japan)
  • Almac Group (UK)
  • Vetter Pharma (Germany)
  • Delpharm Holdings (France)
  • Yuhan Corporation (South Korea)
  • Curia Global, Inc. (US)
  • Charles River Laboratories. (US)
  • Lannett Company, Inc. (US)
  • Cambrex Corporation. (US)
  • FAMAR Healthcare Services (France)
  • Biocon Limited (India)
  • Sai Life Sciences Limited (India)
  • PCI Pharma Services (US).
Research Coverage:

This report provides a detailed picture of the pharmaceutical contract development and manufacturing market. It aims at estimating the size and future growth potential of the market across different segments, such as service, end user, and region. The report also includes an in-depth competitive analysis of the key market players, along with their company profiles, recent developments, and key market strategies.

Key Benefits of Buying the Report:

The report will help market leaders/new entrants by providing them with the closest approximations of the revenue numbers for the overall pharmaceutical contract development and manufacturing market and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to better position their business and make suitable go-to-market strategies. This report will enable stakeholders to understand the market's pulse and provide them with information on the key market drivers, restraints, opportunities, and challenges.

The report provides insights on the following pointers:
  • Analysis of key drivers (Increased investment in precision medicines, Patent expiry & increasing demand for generic drugs, High cost of in-house drug development, Investments in advanced manufacturing technologies by CDMOs), restraints (Varying regulatory requirements across various regions), opportunities (Rising demand for cell & gene therapies, Growing inclination toward one-stop-shop model, Market expansion in emerging countries, Growth of nuclear medicine), and challenges (Introduction of serialization, Intellectual property risk) influencing the growth of pharmaceutical contract development and manufacturing market.
  • Service Development/Innovation: Detailed insights on newly launched services, and technological assessment of the pharmaceutical contract development and manufacturing market.
  • Market Development: Comprehensive information about lucrative markets – the report analyses the pharmaceutical contract development and manufacturing market across varied regions.
  • Market Diversification: Exhaustive information about new services, untapped geographies, recent developments, and investments in the pharmaceutical contract development and manufacturing market.
  • Competitive Assessment: In-depth assessment of market shares, growth strategies and service offerings of leading players like Thermo Fisher Scientific Inc. (US), Catalent, Inc. (US), Lonza Group (Switzerland), AbbVie, Inc. (US), WuXi AppTec (China) and among others in the pharmaceutical contract development and manufacturing market.
1 INTRODUCTION

1.1 STUDY OBJECTIVES
1.2 MARKET DEFINITION
  1.2.1 INCLUSIONS AND EXCLUSIONS
1.3 MARKET SCOPE
1.4 YEARS CONSIDERED
1.5 CURRENCY CONSIDERED
1.6 STAKEHOLDERS
1.7 LIMITATIONS
1.8 SUMMARY OF CHANGES
1.9 RECESSION IMPACT

2 RESEARCH METHODOLOGY

2.1 RESEARCH DATA
FIGURE 1 RESEARCH DESIGN
  2.1.1 SECONDARY DATA
  2.1.2 PRIMARY DATA
FIGURE 2 PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET: BREAKDOWN OF PRIMARIES
2.2 MARKET SIZE ESTIMATION
FIGURE 3 PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET SIZE ESTIMATION (SUPPLY-SIDE ANALYSIS), 2022
FIGURE 4 MARKET SIZE ESTIMATION: APPROACH 1 (REVENUE SHARE ANALYSIS), 2022
FIGURE 5 ILLUSTRATIVE EXAMPLE OF THERMO FISHER SCIENTIFIC, INC.: REVENUE SHARE ANALYSIS, 2022
  2.2.1 INSIGHTS FROM PRIMARIES
FIGURE 6 MARKET VALIDATION FROM PRIMARY EXPERTS
  2.2.2 SEGMENT ASSESSMENT (BY SERVICE AND END USER)
FIGURE 7 MARKET SIZE ESTIMATION METHODOLOGY: TOP-DOWN APPROACH
2.3 GROWTH RATE ASSUMPTIONS/GROWTH FORECAST
FIGURE 8 PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET: CAGR PROJECTIONS, 2023–2028
FIGURE 9 PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET: GROWTH ANALYSIS OF DRIVERS, RESTRAINTS, CHALLENGES, AND OPPORTUNITIES
2.4 MARKET BREAKDOWN AND DATA TRIANGULATION
FIGURE 10 DATA TRIANGULATION METHODOLOGY
2.5 RESEARCH ASSUMPTIONS
2.6 RISK ANALYSIS
2.7 IMPACT ANALYSIS OF RECESSION ON PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET
TABLE 1 GLOBAL INFLATION RATE PROJECTIONS, 2024–2027 (% GROWTH)
TABLE 2 US HEALTH EXPENDITURE, 2019–2027 (USD MILLION)
TABLE 3 US HEALTH EXPENDITURE, 2023–2027 (USD MILLION)

3 EXECUTIVE SUMMARY

FIGURE 11 PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY SERVICE, 2023 VS. 2028 (USD BILLION)
FIGURE 12 BIOLOGIC MANUFACTURING SERVICES MARKET, BY TYPE, 2023 VS. 2028 (USD BILLION)
FIGURE 13 PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY END USER, 2023 VS. 2028 (USD BILLION)
FIGURE 14 GEOGRAPHICAL SNAPSHOT: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET

4 PREMIUM INSIGHTS

4.1 PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET OVERVIEW
FIGURE 15 RISING INVESTMENTS IN PHARMACEUTICAL R&D TO DRIVE MARKET GROWTH
4.2 NORTH AMERICA: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY SERVICE & COUNTRY (2022)
FIGURE 16 PHARMACEUTICAL MANUFACTURING SERVICES ACCOUNTED FOR LARGEST SHARE OF NORTH AMERICAN MARKET IN 2022
4.3 PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY SERVICE, 2023 VS. 2028 (USD BILLION)
FIGURE 17 PHARMACEUTICAL MANUFACTURING SERVICES SEGMENT TO DOMINATE MARKET TILL 2028
4.4 PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET SHARE, BY END USER, 2022
FIGURE 18 BIG PHARMACEUTICAL COMPANIES SEGMENT ACCOUNTED FOR LARGEST MARKET SHARE IN 2022
4.5 PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
FIGURE 19 ASIA PACIFIC TO REGISTER HIGHEST GROWTH FROM 2023 TO 2028

5 MARKET OVERVIEW

5.1 INTRODUCTION
5.2 MARKET DYNAMICS
FIGURE 20 PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
TABLE 4 PHARMACEUTICAL CONTRACT MANUFACTURING AND DEVELOPMENT MARKET: IMPACT ANALYSIS
  5.2.1 DRIVERS
    5.2.1.1 Increased investment in precision medicines
    5.2.1.2 Patent expiry & increasing demand for generic drugs
TABLE 5 IMPENDING PATENT EXPIRY OF BLOCKBUSTER DRUGS, BY YEAR
    5.2.1.3 High cost of in-house drug development
FIGURE 21 AVERAGE COST OF DEVELOPING PHARMACEUTICAL COMPOUNDS FROM DISCOVERY TO LAUNCH, 2010–2020 (USD BILLION)
    5.2.1.4 Investments in advanced manufacturing technologies by CDMOs
  5.2.2 RESTRAINTS
    5.2.2.1 Varying regulatory requirements across regions
  5.2.3 OPPORTUNITIES
    5.2.3.1 Rising demand for cell & gene therapy
TABLE 6 EXPANSIONS BY TOP COMPANIES IN 2022
    5.2.3.2 Growing inclination toward one-stop-shop model
    5.2.3.3 Market expansion in emerging countries
    5.2.3.4 Growth of nuclear medicine
  5.2.4 CHALLENGES
    5.2.4.1 Introduction of serialization
    5.2.4.2 Intellectual property risk
5.3 VALUE CHAIN ANALYSIS
FIGURE 22 VALUE CHAIN ANALYSIS: API PRODUCTION AND FORMULATION ADD MAXIMUM VALUE
5.4 ECOSYSTEM ANALYSIS
FIGURE 23 ECOSYSTEM ANALYSIS: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET
TABLE 7 PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET: ROLE IN ECOSYSTEM
5.5 TECHNOLOGY ANALYSIS
5.6 PORTER’S FIVE FORCES ANALYSIS
TABLE 8 PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET: PORTER’S FIVE FORCES ANALYSIS
  5.6.1 THREAT OF NEW ENTRANTS
  5.6.2 THREAT OF SUBSTITUTES
  5.6.3 BARGAINING POWER OF SUPPLIERS
  5.6.4 BARGAINING POWER OF BUYERS
  5.6.5 INTENSITY OF COMPETITIVE RIVALRY
5.7 REGULATORY ANALYSIS
TABLE 9 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 10 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 11 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 12 ROW: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 13 REGULATORY SCENARIO IN DIFFERENT COUNTRIES
5.8 KEY CONFERENCES & EVENTS, 2022–2023
TABLE 14 PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET: DETAILED LIST OF CONFERENCES & EVENTS, 2022–2023
5.9 KEY STAKEHOLDERS AND BUYING CRITERIA
  5.9.1 KEY STAKEHOLDERS IN BUYING PROCESS
FIGURE 24 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF CDMO SERVICES
  5.9.2 BUYING CRITERIA
FIGURE 25 KEY BUYING CRITERIA FOR END USERS
5.10 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESS
FIGURE 26 REVENUE SHIFT & NEW POCKETS FOR PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET
5.11 ANDA APPROVALS
FIGURE 27 ANDA APPROVALS, 2018–2022
FIGURE 28 REGIONAL BREAKDOWN OF ANDA APPROVALS IN 2022
FIGURE 29 ANDA APPROVALS IN 2022, BY DOSAGE FORM

6 PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY SERVICE

6.1 INTRODUCTION
TABLE 15 PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY SERVICE, 2021–2028 (USD BILLION)
6.2 PHARMACEUTICAL MANUFACTURING SERVICES
TABLE 16 PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY TYPE, 2021–2028 (USD BILLION)
TABLE 17 PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY REGION, 2021–2028 (USD BILLION)
TABLE 18 NORTH AMERICA: PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY COUNTRY, 2021–2028 (USD BILLION)
TABLE 19 EUROPE: PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY COUNTRY, 2021–2028 (USD BILLION)
TABLE 20 ASIA PACIFIC: PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY COUNTRY, 2021–2028 (USD BILLION)
TABLE 21 LATIN AMERICA: PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY COUNTRY, 2021–2028 (USD BILLION)
  6.2.1 PHARMACEUTICAL API MANUFACTURING SERVICES
    6.2.1.1 Need to focus on core areas to drive pharma companies to outsource API manufacturing
TABLE 22 PHARMACEUTICAL API MANUFACTURING SERVICES MARKET, BY REGION, 2021–2028 (USD BILLION)
TABLE 23 NORTH AMERICA: PHARMACEUTICAL API MANUFACTURING SERVICES MARKET, BY COUNTRY, 2021–2028 (USD BILLION)
TABLE 24 EUROPE: PHARMACEUTICAL API MANUFACTURING SERVICES MARKET, BY COUNTRY, 2021–2028 (USD BILLION)
TABLE 25 ASIA PACIFIC: PHARMACEUTICAL API MANUFACTURING SERVICES MARKET, BY COUNTRY, 2021–2028 (USD BILLION)
TABLE 26 LATIN AMERICA: PHARMACEUTICAL API MANUFACTURING SERVICES MARKET, BY COUNTRY, 2021–2028 (USD BILLION)
  6.2.2 PHARMACEUTICAL FDF MANUFACTURING SERVICES
TABLE 27 PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY TYPE, 2021–2028 (USD BILLION)
TABLE 28 PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY REGION, 2021–2028 (USD BILLION)
TABLE 29 NORTH AMERICA: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY COUNTRY, 2021–2028 (USD BILLION)
TABLE 30 EUROPE: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY COUNTRY, 2021–2028 (USD BILLION)
TABLE 31 ASIA PACIFIC: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY COUNTRY, 2021–2028 (USD BILLION)
TABLE 32 LATIN AMERICA: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY COUNTRY, 2021–2028 (USD BILLION)
    6.2.2.1 Parenteral/Injectable manufacturing services
      6.2.2.1.1 Increasing investments in drug development to support market growth
TABLE 33 PARENTERAL/INJECTABLE MANUFACTURING SERVICES MARKET, BY REGION, 2021–2028 (USD BILLION)
TABLE 34 NORTH AMERICA: PARENTERAL/INJECTABLE MANUFACTURING SERVICES MARKET, BY COUNTRY, 2021–2028 (USD BILLION)
TABLE 35 EUROPE: PARENTERAL/INJECTABLE MANUFACTURING SERVICES MARKET, BY COUNTRY, 2021–2028 (USD BILLION)
TABLE 36 ASIA PACIFIC: PARENTERAL/INJECTABLE MANUFACTURING SERVICES MARKET, BY COUNTRY, 2021–2028 (USD BILLION)
TABLE 37 LATIN AMERICA: PARENTERAL/INJECTABLE MANUFACTURING SERVICES MARKET, BY COUNTRY, 2021–2028 (USD BILLION)
    6.2.2.2 Tablet manufacturing services
      6.2.2.2.1 Growing production capacity for tablet manufacturing in emerging markets to support growth
TABLE 38 TABLET MANUFACTURING SERVICES MARKET, BY REGION, 2021–2028 (USD BILLION)
TABLE 39 NORTH AMERICA: TABLET MANUFACTURING SERVICES MARKET, BY COUNTRY, 2021–2028 (USD BILLION)
TABLE 40 EUROPE: TABLET MANUFACTURING SERVICES MARKET, BY COUNTRY, 2021–2028 (USD BILLION)
TABLE 41 ASIA PACIFIC: TABLET MANUFACTURING SERVICES MARKET, BY COUNTRY, 2021–2028 (USD BILLION)
TABLE 42 LATIN AMERICA: TABLET MANUFACTURING SERVICES MARKET, BY COUNTRY, 2021–2028 (USD BILLION)
    6.2.2.3 Capsule manufacturing services
      6.2.2.3.1 Popularity of capsules to ensure demand for contract manufacturing
TABLE 43 CAPSULE MANUFACTURING SERVICES MARKET, BY REGION, 2021–2028 (USD BILLION)
TABLE 44 NORTH AMERICA: CAPSULE MANUFACTURING SERVICES MARKET, BY COUNTRY, 2021–2028 (USD BILLION)
TABLE 45 EUROPE: CAPSULE MANUFACTURING SERVICES MARKET, BY COUNTRY, 2021–2028 (USD BILLION)
TABLE 46 ASIA PACIFIC: CAPSULE MANUFACTURING SERVICES MARKET, BY COUNTRY, 2021–2028 (USD BILLION)
TABLE 47 LATIN AMERICA: CAPSULE MANUFACTURING SERVICES MARKET, BY COUNTRY, 2021–2028 (USD BILLION)
    6.2.2.4 Oral liquid manufacturing services
      6.2.2.4.1 Complexities in handling liquids to promote outsourcing
TABLE 48 ORAL LIQUID MANUFACTURING SERVICES MARKET, BY REGION, 2021–2028 (USD BILLION)
TABLE 49 NORTH AMERICA: ORAL LIQUID MANUFACTURING SERVICES MARKET, BY COUNTRY, 2021–2028 (USD BILLION)
TABLE 50 EUROPE: ORAL LIQUID MANUFACTURING SERVICES MARKET, BY COUNTRY, 2021–2028 (USD BILLION)
TABLE 51 ASIA PACIFIC: ORAL LIQUID MANUFACTURING SERVICES MARKET, BY COUNTRY, 2021–2028 (USD BILLION)
TABLE 52 LATIN AMERICA: ORAL LIQUID MANUFACTURING SERVICES MARKET, BY COUNTRY, 2021–2028 (USD BILLION)
    6.2.2.5 Semi-solid manufacturing services
      6.2.2.5.1 Need for specialized facilities to boost outsourcing of semi-solid manufacturing
TABLE 53 SEMI-SOLID MANUFACTURING SERVICES MARKET, BY REGION, 2021–2028 (USD BILLION)
TABLE 54 NORTH AMERICA: SEMI-SOLID MANUFACTURING SERVICES MARKET, BY COUNTRY, 2021–2028 (USD BILLION)
TABLE 55 EUROPE: SEMI-SOLID MANUFACTURING SERVICES MARKET, BY COUNTRY, 2021–2028 (USD BILLION)
TABLE 56 ASIA PACIFIC: SEMI-SOLID MANUFACTURING SERVICES MARKET, BY COUNTRY, 2021–2028 (USD BILLION)
TABLE 57 LATIN AMERICA: SEMI-SOLID MANUFACTURING SERVICES MARKET, BY COUNTRY, 2021–2028 (USD BILLION)
    6.2.2.6 Other FDF manufacturing services
TABLE 58 OTHER FDF MANUFACTURING SERVICES MARKET, BY REGION, 2021–2028 (USD BILLION)
TABLE 59 NORTH AMERICA: OTHER FDF MANUFACTURING SERVICES MARKET, BY COUNTRY, 2021–2028 (USD BILLION)
TABLE 60 EUROPE: OTHER FDF MANUFACTURING SERVICES MARKET, BY COUNTRY, 2021–2028 (USD BILLION)
TABLE 61 ASIA PACIFIC: OTHER FDF MANUFACTURING SERVICES MARKET, BY COUNTRY, 2021–2028 (USD BILLION)
TABLE 62 LATIN AMERICA: OTHER FDF MANUFACTURING SERVICES MARKET, BY COUNTRY, 2021–2028 (USD BILLION)
6.3 DRUG DEVELOPMENT SERVICES
  6.3.1 HIGH COST OF DEVELOPMENT TO BOOST OUTSOURCING
TABLE 63 DRUG DEVELOPMENT SERVICES MARKET, BY REGION, 2021–2028 (USD BILLION)
TABLE 64 NORTH AMERICA: DRUG DEVELOPMENT SERVICES MARKET, BY COUNTRY, 2021–2028 (USD BILLION)
TABLE 65 EUROPE: DRUG DEVELOPMENT SERVICES MARKET, BY COUNTRY, 2021–2028 (USD BILLION)
TABLE 66 ASIA PACIFIC: DRUG DEVELOPMENT SERVICES MARKET, BY COUNTRY, 2021–2028 (USD BILLION)
TABLE 67 LATIN AMERICA: DRUG DEVELOPMENT SERVICES MARKET, BY COUNTRY, 2021–2028 (USD BILLION)
6.4 BIOLOGIC MANUFACTURING SERVICES
TABLE 68 BIOLOGIC MANUFACTURING SERVICES MARKET, BY TYPE, 2021–2028 (USD BILLION)
TABLE 69 BIOLOGIC MANUFACTURING SERVICES MARKET, BY REGION, 2021–2028 (USD BILLION)
TABLE 70 NORTH AMERICA: BIOLOGIC MANUFACTURING SERVICES MARKET, BY COUNTRY, 2021–2028 (USD BILLION)
TABLE 71 EUROPE: BIOLOGIC MANUFACTURING SERVICES MARKET, BY COUNTRY, 2021–2028 (USD BILLION)
TABLE 72 ASIA PACIFIC: BIOLOGIC MANUFACTURING SERVICES MARKET, BY COUNTRY, 2021–2028 (USD BILLION)
TABLE 73 LATIN AMERICA: BIOLOGIC MANUFACTURING SERVICES MARKET, BY COUNTRY, 2021–2028 (USD BILLION)
  6.4.1 BIOLOGIC API MANUFACTURING SERVICES
    6.4.1.1 Rising interest in biologics to ensure growth of nascent contract manufacturing sector
TABLE 74 BIOLOGIC API MANUFACTURING SERVICES MARKET, BY REGION, 2021–2028 (USD BILLION)
TABLE 75 NORTH AMERICA: BIOLOGIC API MANUFACTURING SERVICES MARKET, BY COUNTRY, 2021–2028 (USD BILLION)
TABLE 76 EUROPE: BIOLOGIC API MANUFACTURING SERVICES MARKET, BY COUNTRY, 2021–2028 (USD BILLION)
TABLE 77 ASIA PACIFIC: BIOLOGIC API MANUFACTURING SERVICES MARKET, BY COUNTRY, 2021–2028 (USD BILLION)
TABLE 78 LATIN AMERICA: BIOLOGIC API MANUFACTURING SERVICES MARKET, BY COUNTRY, 2021–2028 (USD BILLION)
  6.4.2 BIOLOGIC FDF MANUFACTURING SERVICES
    6.4.2.1 Growing R&D costs and process complexity to favor contract manufacturing
TABLE 79 BIOLOGIC FDF MANUFACTURING SERVICES MARKET, BY REGION, 2021–2028 (USD BILLION)
TABLE 80 NORTH AMERICA: BIOLOGIC FDF MANUFACTURING SERVICES MARKET, BY COUNTRY, 2021–2028 (USD BILLION)
TABLE 81 EUROPE: BIOLOGIC FDF MANUFACTURING SERVICES MARKET, BY COUNTRY, 2021–2028 (USD BILLION)
TABLE 82 ASIA PACIFIC: BIOLOGIC FDF MANUFACTURING SERVICES MARKET, BY COUNTRY, 2021–2028 (USD BILLION)
TABLE 83 LATIN AMERICA: BIOLOGIC FDF MANUFACTURING SERVICES MARKET, BY COUNTRY, 2021–2028 (USD BILLION)

7 PHARMACEUTICAL CONTRACT DEVELOPMENT AND

MANUFACTURING MARKET, BY END USER
7.1 INTRODUCTION
TABLE 84 PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY END USER, 2021–2028 (USD BILLION)
7.2 BIG PHARMACEUTICAL COMPANIES
  7.2.1 EMERGENCE OF NEW MEDICINES AND THERAPIES TO CONTRIBUTE TO MARKET GROWTH
TABLE 85 PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET FOR BIG PHARMACEUTICAL COMPANIES, BY COUNTRY, 2021–2028 (USD BILLION)
TABLE 86 NORTH AMERICA: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET FOR BIG PHARMACEUTICAL COMPANIES, BY COUNTRY, 2021–2028 (USD BILLION)
TABLE 87 EUROPE: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET FOR BIG PHARMACEUTICAL COMPANIES, BY COUNTRY, 2021–2028 (USD BILLION)
TABLE 88 ASIA PACIFIC: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET FOR BIG PHARMACEUTICAL COMPANIES, BY COUNTRY, 2021–2028 (USD BILLION)
TABLE 89 LATIN AMERICA: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET FOR BIG PHARMACEUTICAL COMPANIES, BY COUNTRY, 2021–2028 (USD BILLION)
7.3 SMALL & MEDIUM-SIZED PHARMACEUTICAL COMPANIES
  7.3.1 GROWING DEVELOPMENT OF BIOLOGICS AND HIGH PRICING PRESSURE TO BOOST MARKET
TABLE 90 PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET FOR SMALL & MEDIUM-SIZED PHARMACEUTICAL COMPANIES, BY REGION, 2021–2028 (USD BILLION)
TABLE 91 NORTH AMERICA: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET FOR SMALL & MEDIUM-SIZED PHARMACEUTICAL COMPANIES, BY COUNTRY, 2021–2028 (USD BILLION)
TABLE 92 EUROPE: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET FOR SMALL & MEDIUM-SIZED PHARMACEUTICAL COMPANIES, BY COUNTRY, 2021–2028 (USD BILLION)
TABLE 93 ASIA PACIFIC: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET FOR SMALL & MEDIUM-SIZED PHARMACEUTICAL COMPANIES, BY COUNTRY, 2021–2028 (USD BILLION)
TABLE 94 LATIN AMERICA: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET FOR SMALL & MEDIUM-SIZED PHARMACEUTICAL COMPANIES, BY COUNTRY, 2021–2028 (USD BILLION)
7.4 GENERIC PHARMACEUTICAL COMPANIES
  7.4.1 RISING DEMAND FOR GENERICS TO PROPEL MARKET
TABLE 95 PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET FOR GENERIC PHARMACEUTICAL COMPANIES, BY REGION, 2021–2028 (USD BILLION)
TABLE 96 NORTH AMERICA: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET FOR GENERIC PHARMACEUTICAL COMPANIES, BY COUNTRY, 2021–2028 (USD BILLION)
TABLE 97 EUROPE: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET FOR GENERIC PHARMACEUTICAL COMPANIES, BY COUNTRY, 2021–2028 (USD BILLION)
TABLE 98 ASIA PACIFIC: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET FOR GENERIC PHARMACEUTICAL COMPANIES, BY COUNTRY, 2021–2028 (USD BILLION)
TABLE 99 LATIN AMERICA PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET FOR GENERIC PHARMACEUTICAL COMPANIES, BY COUNTRY, 2021–2028 (USD BILLION)
7.5 OTHER END USERS
TABLE 100 PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET FOR OTHER END USERS, BY REGION, 2021–2028 (USD BILLION)
TABLE 101 NORTH AMERICA: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET FOR OTHER END USERS, BY COUNTRY, 2021–2028 (USD BILLION)
TABLE 102 EUROPE: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET FOR OTHER END USERS, BY COUNTRY, 2021–2028 (USD BILLION)
TABLE 103 ASIA PACIFIC: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET FOR OTHER END USERS, BY COUNTRY, 2021–2028 (USD BILLION)
TABLE 104 LATIN AMERICA: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET FOR OTHER END USERS, BY COUNTRY, 2021–2028 (USD BILLION)

8 PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY REGION

8.1 INTRODUCTION
TABLE 105 PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY REGION, 2021–2028 (USD BILLION)
8.2 NORTH AMERICA
FIGURE 30 NORTH AMERICA: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET SNAPSHOT
TABLE 106 NORTH AMERICA: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY COUNTRY, 2021–2028 (USD BILLION)
TABLE 107 NORTH AMERICA: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY SERVICE, 2021–2028 (USD BILLION)
TABLE 108 NORTH AMERICA: PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY TYPE, 2021–2028 (USD BILLION)
TABLE 109 NORTH AMERICA: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY TYPE, 2021–2028 (USD BILLION)
TABLE 110 NORTH AMERICA: BIOLOGIC MANUFACTURING SERVICES MARKET, BY TYPE, 2021–2028 (USD BILLION)
TABLE 111 NORTH AMERICA: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY END USER, 2021–2028 (USD BILLION)
  8.2.1 US
    8.2.1.1 US to dominate North American market
TABLE 112 US: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY SERVICE, 2021–2028 (USD BILLION)
TABLE 113 US: PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY TYPE, 2021–2028 (USD BILLION)
TABLE 114 US: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY TYPE, 2021–2028 (USD BILLION)
TABLE 115 US: BIOLOGIC MANUFACTURING SERVICES MARKET, BY TYPE, 2021–2028 (USD BILLION)
TABLE 116 US: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY END USER, 2021–2028 (USD BILLION)
  8.2.2 CANADA
    8.2.2.1 Rising government funding and support to propel market
TABLE 117 CANADA: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY SERVICE, 2021–2028 (USD BILLION)
TABLE 118 CANADA: PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY TYPE, 2021–2028 (USD BILLION)
TABLE 119 CANADA: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY TYPE, 2021–2028 (USD BILLION)
TABLE 120 CANADA: BIOLOGIC MANUFACTURING SERVICES MARKET, BY TYPE, 2021–2028 (USD BILLION)
TABLE 121 CANADA: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY END USER, 2021–2028 (USD BILLION)
  8.2.3 NORTH AMERICA: RECESSION IMPACT
8.3 EUROPE
TABLE 122 EUROPE: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY COUNTRY, 2021–2028 (USD BILLION)
TABLE 123 EUROPE: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY SERVICE, 2021–2028 (USD BILLION)
TABLE 124 EUROPE: PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY TYPE, 2021–2028 (USD BILLION)
TABLE 125 EUROPE: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY TYPE, 2021–2028 (USD BILLION)
TABLE 126 EUROPE: BIOLOGIC MANUFACTURING SERVICES MARKET, BY TYPE, 2021–2028 (USD BILLION)
TABLE 127 EUROPE: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY END USER, 2021–2028 (USD BILLION)
  8.3.1 GERMANY
    8.3.1.1 Germany to hold largest share throughout forecast period
TABLE 128 GERMANY: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY SERVICE, 2021–2028 (USD BILLION)
TABLE 129 GERMANY: PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY TYPE, 2021–2028 (USD BILLION)
TABLE 130 GERMANY: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY TYPE, 2021–2028 (USD BILLION)
TABLE 131 GERMANY: BIOLOGIC MANUFACTURING SERVICES MARKET, BY TYPE, 2021–2028 (USD BILLION)
TABLE 132 GERMANY: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY END USER, 2021–2028 (USD BILLION)
  8.3.2 UK
    8.3.2.1 Rising investments in drug development to favor market growth
TABLE 133 UK: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY SERVICE, 2021–2028 (USD BILLION)
TABLE 134 UK: PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY TYPE, 2021–2028 (USD BILLION)
TABLE 135 UK: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY TYPE, 2021–2028 (USD BILLION)
TABLE 136 UK: BIOLOGIC MANUFACTURING SERVICES MARKET, BY TYPE, 2021–2028 (USD BILLION)
TABLE 137 UK: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY END USER, 2021–2028 (USD BILLION)
  8.3.3 FRANCE
    8.3.3.1 Growing generics segment, favorable government policies, and growing clinical trials to drive market
TABLE 138 FRANCE: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY SERVICE, 2021–2028 (USD BILLION)
TABLE 139 FRANCE: PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY TYPE, 2021–2028 (USD BILLION)
TABLE 140 FRANCE: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY TYPE, 2021–2028 (USD BILLION)
TABLE 141 FRANCE: BIOLOGIC MANUFACTURING SERVICES MARKET, BY TYPE, 2021–2028 (USD BILLION)
TABLE 142 FRANCE: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY END USER, 2021–2028 (USD BILLION)
  8.3.4 ITALY
    8.3.4.1 Rising commercial drug development pipeline in Europe to favor market growth
TABLE 143 ITALY: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY SERVICE, 2021–2028 (USD BILLION)
TABLE 144 ITALY: PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY TYPE, 2021–2028 (USD BILLION)
TABLE 145 ITALY: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY TYPE, 2021–2028 (USD BILLION)
TABLE 146 ITALY: BIOLOGIC MANUFACTURING SERVICES MARKET, BY TYPE, 2021–2028 (USD BILLION)
TABLE 147 ITALY: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY END USER, 2021–2028 (USD BILLION)
  8.3.5 SWITZERLAND
    8.3.5.1 Growing pharmaceutical industry to support growth
TABLE 148 SWITZERLAND: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY SERVICE, 2021–2028 (USD BILLION)
TABLE 149 SWITZERLAND: PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY TYPE, 2021–2028 (USD BILLION)
TABLE 150 SWITZERLAND: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY TYPE, 2021–2028 (USD BILLION)
TABLE 151 SWITZERLAND: BIOLOGIC MANUFACTURING SERVICES MARKET, BY TYPE, 2021–2028 (USD BILLION)
TABLE 152 SWITZERLAND: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY END USER, 2021–2028 (USD BILLION)
  8.3.6 POLAND
    8.3.6.1 Increasing support for life science R&D to propel market
TABLE 153 POLAND: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY SERVICE, 2021–2028 (USD BILLION)
TABLE 154 POLAND: PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY TYPE, 2021–2028 (USD BILLION)
TABLE 155 POLAND: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY TYPE, 2021–2028 (USD BILLION)
TABLE 156 POLAND: BIOLOGIC MANUFACTURING SERVICES MARKET, BY TYPE, 2021–2028 (USD BILLION)
TABLE 157 POLAND: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY END USER, 2021–2028 (USD BILLION)
  8.3.7 SPAIN
    8.3.7.1 Rising R&D expenditure to boost market
TABLE 158 SPAIN: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY SERVICE, 2021–2028 (USD BILLION)
TABLE 159 SPAIN: PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY TYPE, 2021–2028 (USD BILLION)
TABLE 160 SPAIN: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY TYPE, 2021–2028 (USD BILLION)
TABLE 161 SPAIN: BIOLOGIC MANUFACTURING SERVICES MARKET, BY TYPE, 2021–2028 (USD BILLION)
TABLE 162 SPAIN: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY END USER, 2021–2028 (USD BILLION)
  8.3.8 REST OF EUROPE
TABLE 163 REST OF EUROPE: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY SERVICE, 2021–2028 (USD BILLION)
TABLE 164 REST OF EUROPE: PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY TYPE, 2021–2028 (USD BILLION)
TABLE 165 REST OF EUROPE: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY TYPE, 2021–2028 (USD BILLION)
TABLE 166 REST OF EUROPE: BIOLOGIC MANUFACTURING SERVICES MARKET, BY TYPE, 2021–2028 (USD BILLION)
TABLE 167 REST OF EUROPE: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY END USER, 2021–2028 (USD BILLION)
  8.3.9 EUROPE: RECESSION IMPACT
8.4 ASIA PACIFIC
FIGURE 31 ASIA PACIFIC: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET SNAPSHOT
TABLE 168 ASIA PACIFIC: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY COUNTRY, 2021–2028 (USD BILLION)
TABLE 169 ASIA PACIFIC: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY SERVICE, 2021–2028 (USD BILLION)
TABLE 170 ASIA PACIFIC: PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY TYPE, 2021–2028 (USD BILLION)
TABLE 171 ASIA PACIFIC: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY TYPE, 2021–2028 (USD BILLION)
TABLE 172 ASIA PACIFIC: BIOLOGIC MANUFACTURING SERVICES MARKET, BY TYPE, 2021–2028 (USD BILLION)
TABLE 173 ASIA PACIFIC: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY END USER, 2021–2028 (USD BILLION)
  8.4.1 CHINA
    8.4.1.1 China to hold largest share of Asia Pacific market
TABLE 174 CHINA: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY SERVICE, 2021–2028 (USD BILLION)
TABLE 175 CHINA: PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY TYPE, 2021–2028 (USD BILLION)
TABLE 176 CHINA: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY TYPE, 2021–2028 (USD BILLION)
TABLE 177 CHINA: BIOLOGIC MANUFACTURING SERVICES MARKET, BY TYPE, 2021–2028 (USD BILLION)
TABLE 178 CHINA: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY END USER, 2021–2028 (USD BILLION)
  8.4.2 INDIA
    8.4.2.1 Increasing pharma R&D activities and government funding for biotechnology to support market growth
TABLE 179 INDIA: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY SERVICE, 2021–2028 (USD BILLION)
TABLE 180 INDIA: PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY TYPE, 2021–2028 (USD BILLION)
TABLE 181 INDIA: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY TYPE, 2021–2028 (USD BILLION)
TABLE 182 INDIA: BIOLOGIC MANUFACTURING SERVICES MARKET, BY TYPE, 2021–2028 (USD BILLION)
TABLE 183 INDIA: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY END USER, 2021–2028 (USD BILLION)
  8.4.3 JAPAN
    8.4.3.1 Growing generics demand and government initiatives to drive demand for contract manufacturing
TABLE 184 JAPAN: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY SERVICE, 2021–2028 (USD BILLION)
TABLE 185 JAPAN: PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY TYPE, 2021–2028 (USD BILLION)
TABLE 186 JAPAN: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY TYPE, 2021–2028 (USD BILLION)
TABLE 187 JAPAN: BIOLOGIC MANUFACTURING SERVICES MARKET, BY TYPE, 2021–2028 (USD BILLION)
TABLE 188 JAPAN: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY END USER, 2021–2028 (USD BILLION)
  8.4.4 SOUTH KOREA
    8.4.4.1 Government initiatives and growing R&D activities for drug development to drive market growth
TABLE 189 SOUTH KOREA: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY SERVICE, 2021–2028 (USD BILLION)
TABLE 190 SOUTH KOREA: PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY TYPE, 2021–2028 (USD BILLION)
TABLE 191 SOUTH KOREA: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY TYPE, 2021–2028 (USD BILLION)
TABLE 192 SOUTH KOREA: BIOLOGIC MANUFACTURING SERVICES MARKET, BY TYPE, 2021–2028 (USD BILLION)
TABLE 193 SOUTH KOREA: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY END USER, 2021–2028 (USD BILLION)
  8.4.5 REST OF ASIA PACIFIC
TABLE 194 REST OF ASIA PACIFIC: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY SERVICE, 2021–2028 (USD BILLION)
TABLE 195 REST OF ASIA PACIFIC: PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY TYPE, 2021–2028 (USD BILLION)
TABLE 196 REST OF ASIA PACIFIC: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY TYPE, 2021–2028 (USD BILLION)
TABLE 197 REST OF ASIA PACIFIC: BIOLOGIC MANUFACTURING SERVICES MARKET, BY TYPE, 2021–2028 (USD BILLION)
TABLE 198 REST OF ASIA PACIFIC: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY END USER, 2021–2028 (USD BILLION)
  8.4.6 ASIA PACIFIC: RECESSION IMPACT
8.5 LATIN AMERICA
TABLE 199 LATIN AMERICA: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY COUNTRY, 2021–2028 (USD BILLION)
TABLE 200 LATIN AMERICA: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY SERVICE, 2021–2028 (USD BILLION)
TABLE 201 LATIN AMERICA: PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY TYPE, 2021–2028 (USD BILLION)
TABLE 202 LATIN AMERICA: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY TYPE, 2021–2028 (USD BILLION)
TABLE 203 LATIN AMERICA: BIOLOGIC MANUFACTURING SERVICES MARKET, BY TYPE, 2021–2028 (USD BILLION)
TABLE 204 LATIN AMERICA: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY END USER, 2021–2028 (USD BILLION)
  8.5.1 BRAZIL
    8.5.1.1 Growing pharmaceutical industry to drive market
TABLE 205 BRAZIL: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY SERVICE, 2021–2028 (USD BILLION)
TABLE 206 BRAZIL: PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY TYPE, 2021–2028 (USD BILLION)
TABLE 207 BRAZIL: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY TYPE, 2021–2028 (USD BILLION)
TABLE 208 BRAZIL: BIOLOGIC MANUFACTURING SERVICES MARKET, BY TYPE, 2021–2028 (USD BILLION)
TABLE 209 BRAZIL: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY END USER, 2021–2028 (USD BILLION)
  8.5.2 REST OF LATIN AMERICA
TABLE 210 REST OF LATIN AMERICA: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY SERVICE, 2021–2028 (USD BILLION)
TABLE 211 REST OF LATIN AMERICA: PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY TYPE, 2021–2028 (USD BILLION)
TABLE 212 REST OF LATIN AMERICA: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY TYPE, 2021–2028 (USD BILLION)
TABLE 213 REST OF LATIN AMERICA: BIOLOGIC MANUFACTURING SERVICES MARKET, BY TYPE, 2021–2028 (USD BILLION)
TABLE 214 REST OF LATIN AMERICA: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY END USER, 2021–2028 (USD BILLION)
  8.5.3 LATIN AMERICA: RECESSION IMPACT
8.6 MIDDLE EAST & AFRICA
  8.6.1 UAE AND SAUDI ARABIA TO SHOW SIGNIFICANT GROWTH
TABLE 215 MIDDLE EAST & AFRICA: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY SERVICE, 2021–2028 (USD BILLION)
TABLE 216 MIDDLE EAST & AFRICA: PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY TYPE, 2021–2028 (USD BILLION)
TABLE 217 MIDDLE EAST & AFRICA: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY TYPE, 2021–2028 (USD BILLION)
TABLE 218 MIDDLE EAST & AFRICA: BIOLOGIC MANUFACTURING SERVICES MARKET, BY TYPE, 2021–2028 (USD BILLION)
TABLE 219 MIDDLE EAST & AFRICA: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY END USER, 2021–2028 (USD BILLION)
  8.6.2 MIDDLE EAST & AFRICA: RECESSION IMPACT

9 COMPETITIVE LANDSCAPE

9.1 OVERVIEW
9.2 KEY PLAYER STRATEGIES
TABLE 220 KEY STRATEGIES ADOPTED BY PLAYERS IN PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, 2020–2023
9.3 REVENUE SHARE ANALYSIS
FIGURE 32 REVENUE SHARE ANALYSIS OF KEY PLAYERS, 2020–2022
9.4 MARKET SHARE ANALYSIS
FIGURE 33 PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET SHARE ANALYSIS, BY KEY PLAYER, 2022
TABLE 221 PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET: DEGREE OF COMPETITION
9.5 COMPANY EVALUATION QUADRANT FOR KEY PLAYERS, 2022
  9.5.1 STARS
  9.5.2 EMERGING LEADERS
  9.5.3 PERVASIVE PLAYERS
  9.5.4 PARTICIPANTS
FIGURE 34 PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET: COMPANY EVALUATION QUADRANT, 2022
9.6 COMPETITIVE BENCHMARKING OF TOP 25 PLAYERS
  9.6.1 SERVICE FOOTPRINT OF COMPANIES (25 COMPANIES)
TABLE 222 SERVICE FOOTPRINT ANALYSIS OF KEY PLAYERS IN PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET
  9.6.2 END-USER FOOTPRINT OF COMPANIES (25 COMPANIES)
TABLE 223 END-USER FOOTPRINT ANALYSIS OF KEY PLAYERS IN PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET
  9.6.3 REGIONAL FOOTPRINT OF COMPANIES (25 COMPANIES)
TABLE 224 REGIONAL FOOTPRINT ANALYSIS OF KEY PLAYERS IN PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET
9.7 COMPANY EVALUATION QUADRANT FOR START-UPS/SMES (2022)
  9.7.1 PROGRESSIVE COMPANIES
  9.7.2 STARTING BLOCKS
  9.7.3 RESPONSIVE COMPANIES
  9.7.4 DYNAMIC COMPANIES
FIGURE 35 PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET: COMPANY EVALUATION QUADRANT FOR STARTUPS/SMES, 2022
9.8 COMPETITIVE BENCHMARKING OF START-UPS/SMES
TABLE 225 PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET: DETAILED LIST OF KEY START-UP/SME PLAYERS
TABLE 226 PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET: COMPETITIVE BENCHMARKING OF START-UP/SME PLAYERS
9.9 COMPETITIVE SCENARIO AND TRENDS
  9.9.1 SERVICE LAUNCHES
TABLE 227 PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET: SERVICE LAUNCHES, JANUARY 2020–MARCH 2023
  9.9.2 DEALS
TABLE 228 PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET: DEALS, JANUARY 2020–MARCH 2023
  9.9.3 OTHER DEVELOPMENTS
TABLE 229 PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET: OTHER DEVELOPMENTS, JANUARY 2020–MARCH 2023

10 COMPANY PROFILES

10.1 KEY MARKET PLAYERS
(Business Overview, Services Offered, Recent Developments, and MnM View)*
  10.1.1 THERMO FISHER SCIENTIFIC, INC.
TABLE 230 THERMO FISHER SCIENTIFIC, INC.: BUSINESS OVERVIEW
FIGURE 36 THERMO FISHER SCIENTIFIC, INC.: COMPANY SNAPSHOT (2022)
  10.1.2 CATALENT, INC.
TABLE 231 CATALENT, INC.: BUSINESS OVERVIEW
FIGURE 37 CATALENT, INC.: COMPANY SNAPSHOT (2022)
  10.1.3 LONZA GROUP
TABLE 232 LONZA GROUP: BUSINESS OVERVIEW
FIGURE 38 LONZA GROUP: COMPANY SNAPSHOT (2022)
  10.1.4 ABBVIE, INC.
TABLE 233 ABBVIE, INC.: BUSINESS OVERVIEW
FIGURE 39 ABBVIE, INC.: COMPANY SNAPSHOT (2022)
  10.1.5 WUXI APPTEC
TABLE 234 WUXI APPTEC: BUSINESS OVERVIEW
FIGURE 40 WUXI APPTEC: COMPANY SNAPSHOT (2022)
  10.1.6 EVONIK INDUSTRIES AG
TABLE 235 EVONIK INDUSTRIES AG: BUSINESS OVERVIEW
FIGURE 41 EVONIK INDUSTRIES AG: COMPANY SNAPSHOT (2022)
  10.1.7 SAMSUNG BIOLOGICS
TABLE 236 SAMSUNG BIOLOGICS: BUSINESS OVERVIEW
FIGURE 42 SAMSUNG BIOLOGICS: COMPANY SNAPSHOT (2022)
  10.1.8 BOEHRINGER INGELHEIM INTERNATIONAL GMBH
TABLE 237 BOEHRINGER INGELHEIM INTERNATIONAL GMBH: BUSINESS OVERVIEW
FIGURE 43 BOEHRINGER INGELHEIM INTERNATIONAL GMBH: COMPANY SNAPSHOT (2022)
  10.1.9 SIEGFRIED HOLDING AG
TABLE 238 SIEGFRIED HOLDING AG: BUSINESS OVERVIEW
FIGURE 44 SIEGFRIED HOLDING AG: COMPANY SNAPSHOT (2022)
  10.1.10 FUJIFILM HOLDINGS CORPORATION
TABLE 239 FUJIFILM HOLDINGS CORPORATION: BUSINESS OVERVIEW
FIGURE 45 FUJIFILM HOLDINGS CORPORATION: COMPANY SNAPSHOT (2022)
  10.1.11 EUROFINS SCIENTIFIC
TABLE 240 EUROFINS SCIENTIFIC: BUSINESS OVERVIEW
FIGURE 46 EUROFINS SCIENTIFIC: COMPANY SNAPSHOT (2022)
  10.1.12 PIRAMAL PHARMA SOLUTIONS
TABLE 241 PIRAMAL PHARMA SOLUTIONS: BUSINESS OVERVIEW
FIGURE 47 PIRAMAL PHARMA SOLUTIONS: COMPANY SNAPSHOT (2022)
  10.1.13 RECIPHARM AB
TABLE 242 RECIPHARM AB: BUSINESS OVERVIEW
  10.1.14 ALMAC GROUP
TABLE 243 ALMAC GROUP: BUSINESS OVERVIEW
  10.1.15 VETTER PHARMA
TABLE 244 VETTER PHARMA: BUSINESS OVERVIEW
* Business Overview, Services Offered, Recent Developments, and MnM View might not be captured in case of unlisted companies.
10.2 OTHER PLAYERS
  10.2.1 DELPHARM HOLDINGS
  10.2.2 YUHAN CORPORATION
  10.2.3 CURIA GLOBAL, INC.
  10.2.4 CHARLES RIVER LABORATORIES
  10.2.5 LANNETT COMPANY, INC.
  10.2.6 CAMBREX CORPORATION
  10.2.7 FAMAR HEALTHCARE SERVICES
  10.2.8 SYNGENE INTERNATIONAL LIMITED (BIOCON LIMITED)
  10.2.9 SAI LIFE SCIENCES LIMITED
  10.2.10 PCI PHARMA SERVICES

11 APPENDIX

11.1 DISCUSSION GUIDE
11.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
11.3 CUSTOMIZATION OPTIONS
11.4 RELATED REPORTS
11.5 AUTHOR DETAILS


More Publications